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Abstract: Gastrointestinal tumors are responsible for more cancer-related fatalities than any other
type of tumors, and colorectal and gastric malignancies account for a large part of these diseases.
Thus, there is an urgent need to develop new therapeutic approaches to improve the patients’ outcome
and the tumor microenvironment is a promising arena for the development of such treatments.
In fact, the nature of the microenvironment in the different gastrointestinal tracts may significantly
influence not only tumor development but also the therapy response. In particular, an important
microenvironmental component and a potential therapeutic target is the vasculature. In this context,
the extracellular matrix is a key component exerting an active effect in all the hallmarks of cancer,
including angiogenesis. Here, we summarized the current knowledge on the role of extracellular
matrix in affecting endothelial cell function and intratumoral vascularization in the context of colorectal
and gastric cancer. The extracellular matrix acts both directly on endothelial cells and indirectly
through its remodeling and the consequent release of growth factors. We envision that a deeper
understanding of the role of extracellular matrix and of its remodeling during cancer progression is
of chief importance for the development of new, more efficacious, targeted therapies.
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1. Introduction
Gastrointestinal (GI) cancers represent one of the major causes of cancer-related deaths worldwide.
This group of tumors comprises colon, stomach, and liver cancers which altogether account for most of
the fatalities [1]. In addition, despite being less common, the group includes also the pancreatic ductal
adenocarcinoma, characterized by an extremely poor prognosis, and esophagus cancer [1,2]. Like all
cancers, GI tumors arise following the acquisition of oncogenic mutations and, for the stomach, small
intestine, and colorectum, the likelihood of this event could be linked to the short lifespan of epithelial
cells, which must be replaced every few days to overcome the physical, chemical, and biological
insults [3]. GI patients are often diagnosed at advanced stages of the disease, which dramatically
reduces the chances of effective cures. Thus, to improve the survival rate of these patients there is a
need to develop new therapeutic strategies.
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In the past years, an extensive effort has been drawn to characterize the driving mutations of
tumor cells in order to employ more specific drugs, with only partial positive responses in a small
percentage of gastric cancer (GC) patients [4,5]. Despite vast preventive screening that has improved
the five-year survival rate of colorectal cancer (CRC), metastatic CRC still represents a major health
threat. Targeted therapies, such as the use of epidermal growth factor receptor (EGFR) inhibitors,
provide only partial responses and for a limited period of time [6,7], with the Kirsten-rat sarcoma 2
viral oncogene homolog (KRAS) mutation status being predictive of the response [8]. In addition,
a peculiar trait of CRC is that its natural history is highly dependent on the inflammatory processes
that are often at work in this tumor.
An increasing number of studies have demonstrated that the nature and composition of the
tumor microenvironment (TME) can profoundly affect tumor progression and represents an important
mean for the development of new therapeutic approaches to overcome this clinical stumble [9,10].
In fact, tumor progression is the result of a continuous crosstalk between cancer cells and the
surrounding microenvironment. The TME is composed of a variety of cells including endothelial
cells (ECs), fibroblast, and immune cells, and by secreted proteic components such as cytokines,
growth factors, and the extracellular matrix (ECM), with the normal as well as the neoplastic cellular
components being nourished by the newly formed vascular network [11]. These components exchange
a large amount of molecular information with cancer cells that not only affect their growth and
progression but also dramatically influence the therapeutic response and the patient’s outcome [12].
Despite the inflammatory response being generally meant to destroy neoplastic cells, once recruited
inflammatory cells can be reprogrammed by neoplastic cells and by the TME into a tumor-promoting
phenotype [13,14]. Cancer-associated fibroblasts and macrophages significantly affect the development
of GI tumors [15,16] and immunotherapy has been shown to be effective, at least in a subset of CRC
patients [17–19].
Given the above scenario, a more accurate understanding of the relationships of the crosstalk
between cancer cells and the TME cellular and stromal components may grant the possibility to
improve the prognostic accuracy and treatment choices for GI cancer patients.
As previously mentioned, an important component of the TME is the ECM. The importance of the
ECM is highlighted by the fact that it can influence all the hallmarks of cancer identified by Hanahan
and Weinberg [20], impinging on restless proliferation, evasion from tumor suppression, replicative
immortality, resistance to cell death, initiation of cell invasion, abnormal cellular energetics, and
avoidance of the immune response and chronic inflammation, as well as induction of angiogenesis [21].
Once seen as a mere scaffold for cells, providing mechanical and structural support, the ECM can
instead profoundly influence cell function and its dysregulation during cancer growth deeply affects
cancer progression [22–24]. For example, the degradation of the basement membrane (BM) components
of ECM represents a crucial step during GI tumor development [25,26].
Of particular interest is the purpose of ECM in tumor angiogenesis, a pathological process
engaged by tumor cells to overcome the shortage of oxygen and nutrients [27–29]. In the last few
decades, extensive efforts were undertaken to develop new tools to target ECs, with the advantage
that these cells are more stable compared to cancer cells. These endeavors have led to the discovery
of several anti-angiogenic proteins, some of which were brought to clinical trials. These angiostatic
factors are often the result of proteolytic degradation of ECM constituents and act both directly on
ECs, through the binding to receptors on the EC surface, or indirectly modulating the growth factor
availability [30]. Given its strategic role the remodeling of the ECM is finely regulated [24,31]. In this
survey, we will review the current knowledge on how the ECM regulates angiogenesis in the context
of GC and CRC. These tumor types respond differently to anti-angiogenic therapy and the use of the
vascular endothelial growth factor A (VEGFA) blocking agent bevacizumab is currently applied only
in metastatic CRC [32–34], further highlighting the key role of the TME in the regulation of tumor
angiogenesis and the therapy response.
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2. ECM and Angiogenesis: Highlights in GI Cancers
The ECM plays a renowned function in angiogenesis and several are the molecules affecting EC
in a positive or negative way. Thus, the effect that ECM exerts in the angiogenic process is complex
and is the result of the balance between promoting and hindering forces, depending on the relative
concentration of the molecules in a given tissue. Here, we will deal with the ECM molecules which are
most relevant in the vascularization of GC and CRC, and a schematic representation of the major ECM
molecules affecting GI tumor-associated angiogenesis is reported in Figure 1.
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Laminins (LMs) are major components of the epithelial and endothelial basement membrane (BM)
and play an important role in the regulation of tissue homeostasis [35–37] and vessel stability [38].
Several LM isoforms are expressed in the human intestine, including LM-111 (the numbers refer to
the α, β, and γ chain isoform, respectively), LM-511, and LM-332 with specific deposition patterns
along the crypt-villus axis during development and in the blood vessels [39,40]. As further evidence
of the importance of LMs in this tissue, the expression of the LM α1 and α5 chains (LMα1 and
LMα5, respectively) in patients affected by intestinal bowel disease (IBD) are upregulated, suggesting
that they may play an important role in the microenvironmental response to inflammation [41].
Of note, LMα1 is over-expressed in CRC [42] and associates with increased recruitment of stromal
cells, angiogenesis, and enhanced CRC growth. LMα1 engages an intimate crosstalk between cancer,
stromal, and endothelial cells through the recruitment of cancer-associated fibroblasts (CAFs) and
the induction of VEGFA production via the integrin α2β1-CXCR4 (C-X-C chemokine receptor type
4) complex. A recent study demonstrated that increased the laminin subunit α-5 (LAMA5) gene
expression in tumor cells upregulates Notch signaling, affects EC branching, and inhibits metastatic
CRC growth [43]. These results demonstrate that cancer cells start to produce specific LM chains as a
strategy to promote angiogenesis and to facilitate metastatic spread; thus, the inhibition of vascular
BM laminins’ expression may represent a useful therapeutic approach to impair the development of
hepatic metastases of CRC.
Collagens, the main structural proteins of the ECM, are known to profoundly affect EC survival and
vessel formation and it is well known that angiogenesis depends on proper collagens’ biosynthesis and
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cross-linking [44,45]. The major players of this family are the interstitial type I and the BM-associated
collagens type IV, XV, and XVIII. However, a striking imbalance of ECM composition is observed in GI
malignancies and, particularly, in CRC where an increased expression of type I collagen is accompanied
with the reduction of type IV [46,47]. It has been suggested that these modifications may impact on EC
behavior and tumor angiogenesis.
The BM collagens-derived matrikines, bioactive fragments originated through degradation,
have been broadly studied in the context of GI disorders where extensive turnover of BM takes place.
In fact, an increased release of type IV collagen fragments can be detected in the blood stream of CRC
patients [48], as well as in other GI disorders [49], that may function as putative prognostic biomarkers
of the diseases [50].
The best described matrikine is endostatin, the noncollagenous domain 1 (NC-1) domain of type
XVIII collagen α1 chain, which has been extensively characterized for its anti-angiogenic and anti-tumor
activities [51]. In a wide number of clinical studies recombinant human endostatin (Endostar) was
successfully employed in the treatment of CRC and GC [52,53]. Liang and colleagues employed a
Salmonella typhimurium mutant (S636) to specifically deliver endostatin in colon cancer cells, proposing
a new intriguing therapeutic strategy [54], and the use of endostatin was proven effective also in
patients with liver metastasis [55].
Among the type IV collagen-derived matrikines, arresten, an antiangiogenic bioactive fragment
derived from the α1 chain of collagen IV, reduced CRC growth and decreased microvessel density
in preclinical settings [56], but it has not been assessed as possible therapeutic agent in human GI
malignancies yet.
Canstatin, a type IV collagen α2 chain-derived matrikine able to reduce tumor growth and
blood vessel density, has been successfully employed in the treatment of CRC [57] and GC [58]
xenograft models.
Similar properties are shared by tumstatin, another type IV collagen fragment [59,60]. However,
the over-expression of endogenous inhibitors like tumstatin, but also endostatin or thrombospondin-1
(TSP-1), induces the upregulation of angiopoietin-2, basic fibroblast growth factor (bFGF) and
platelet-derived growth factor type A (PDGF-A) in colon cancer cells as a mechanism of escape
from anti-angiogenic stimuli [61], and the use of these fragments is more effective when used in
combination with other angiogenic inhibitors or conventional chemotherapy/radiotherapy. Wei and
colleagues cleverly exploited the Bifidobacterium longum, which localizes and proliferates in the hypoxic
angiogenic environment surrounding solid tumors for tumstatin-targeted delivery, showing significant
reduction of tumor growth and microvessel density [62].
Another ubiquitous ECM component is fibronectin, a multifunctional ECM glycoprotein with
established pro-angiogenic function [63–69], which is often upregulated in several solid cancers,
including CRC [70]. Its alternatively spliced extra domain A (EDA), considered a marker of angiogenesis
and tissue remodeling, is of particular interest in the GI context being over-expressed in dextran
sodium sulfate (DSS)-induced experimental colitis models and in patients with inflammatory bowel
disease (IBD) [71]. CRC cell-derived EDA plays a key role in promoting tumor vasculogenesis and
metastatic spread [72–75]. Interestingly, EC-derived fibronectin expressing the EDA domain enhances
the metastatic capacity of CRC cells inducing the epithelial–mesenchymal transition, highlighting the
role of ECM in modulating a pro-active role of EC on tumor cell behavior [76].
By virtue of their polyhedric nature, proteoglycans affect the development of a wide variety of
tumors, including GI malignancies. However, only a few studies demonstrate a direct implication of
these molecules in GI cancer-associated angiogenesis.
The proteoglycan perlecan and its carboxy-terminal fragment endorepellin best describe
the fundamental balance required to maintain a functional angiogenic system. Unprocessed
perlecan exerts a pro-angiogenic function, whereas its carboxy-terminal fragment endorepellin halts
angiogenesis [77–80]. Perlecan prompts tumor growth and angiogenesis in CRC [81], and its interferon
(IFN)-γ-mediated transcriptional repression may halt the induced angiogenic stimulus [82]. A more
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recent study included perlecan among the ECM molecules that are downregulated by sulindac
treatment in CRC cells [83]. Endorepellin can further be processed by the bone morphogenetic protein
1 (BMP1)/Tolloid-like protease and releases the bioactive angiostatic laminin G-like domain 3 (LG3)
domain, which can also be found in the secretome of CRC cells suggesting that it may play an important
role in this context [84].
Biglycan is another proteoglycan whose expression is altered in CRC, among other cancers [85];
a high expression of this small leucine-rich proteoglycan correlates with poor prognosis [86].
The pro-angiogenic effects of biglycan are exerted through the extracellular signal-regulated
kinase (ERK)-mediated release of VEGFA [87], thus it may represent an important target for
anti-angiogenic therapy.
Hyaluronan, also referred to as hyaluronic acid (HA) or hyaluronate, is a naturally occurring
nonsulfated glycosaminoglycan (GAG) component of connective, epithelial, and neural tissues. It plays
a pivotal role in cancer and its deposition is altered in experimentally induced colitis [88,89]. Hyaluronan
synthesis is finely regulated in vascular cells, highlighting its important role in angiogenesis [90].
Elevated levels of the hyaluronan synthase 1 gene correlate with poor prognosis of CRC patients [91,92],
and its blockage may represent an encouraging therapeutic approach [93].
The role of thrombospondin-1 and -2 (TSP-1 and TSP-2, respectively) as potent endogenous
angiogenesis inhibitors has been extensively studied. Interestingly, TSP-1 expression is reduced in
CRC and inversely correlates with tumor vascularity and prognosis [94–96]. Of note, high levels of
VEGFA combined with the absence of TSP-1 associate to worse outcome in these patients [94,95].
Jo and colleagues demonstrated a gradual wingless/integrated (Wnt)-dependent decrease of TSP-1
expression with tumor progression being almost undetectable in invasive adenocarcinomas [97].
In addition, TSP-1 loss in GI malignancies has also been ascribed to promoter hypermethylation [98,99]
or messenger ribonucleic acid (mRNA) depletion through the microRNAs miR-18, miR-19, and
miR-194 [100]. Intriguingly, TSP-1 null mice are more susceptible to DSS-induced colitis and
display a robust inflammatory-driven angiogenic response [101,102], partially rescued by TSP-mimetic
peptides [101,103]. These studies provide further proof to the current vision about the tight intertwining
interaction between the inflammatory and angiogenic processes [104] and highlight the importance
of investigating negative regulators of angiogenesis also in IBD for potential innovative therapeutic
strategies. TSP-1 and TSP-2 also correlate with interleukin (IL)-10 expression, a further indication
of the crosstalk between angiogenesis and inflammation; accordingly, CRCs expressing IL-10 are
characterized by low vascular density suggesting that it may stimulate the expression of angiostatic
factors [105].
Despite being less studied, compared to the aforementioned ECM molecules, the mindin/F-spondin
family, and in particular spondin-2, displays a strategic function in GI tumor-associated angiogenesis.
Through its pro-migratory effects, it promotes CRC metastatic dissemination [106] and regulates
vessel formation affecting vascular smooth muscle cell proliferation and migration [107]. Spondin-2
expression is regulated by early growth response factor-1 (Egr-1) and it is decreased in CRC tumors [108].
Spondin-2 inhibits EC migration and tube formation and its over-expression impairs angiogenesis
and tumor growth, suggesting that it may function as a potential target for anti-angiogenic therapy
as well as a biomarker for CRC [108]. Intriguingly, also spondin-2 may be involved in the crosstalk
between angiogenesis and inflammation since its expression is induced upon DSS-induced intestinal
inflammation and in turn it activates the nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) promoter through the Toll-like receptor 9 pathway [109]. Spondin-2 is upregulated in GC and
it may regulate angiogenesis also in this tumor context, representing a possible biomarker and/or new
therapeutic target for GC [110].
Multimerin-2 and Elastin microfibril interfacer 2 (EMILIN-2) are two ECM proteins, both belonging
to the EMI domain endowed (EDEN) family [111–114], that display key functions in angiogenesis
and have been extensively studied in the context of GI tumors. Despite their molecular affinity,
multimerin-2 is an angiostatic molecule and functions as a gatekeeper of vascular stability, whereas
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EMILIN-2 promotes angiogenesis. Multimerin-2 is deposited specifically in tight association with
the endothelium [115]. Importantly, multimerin-2 halts the activation of vascular endothelial growth
factor receptor 2 VEGFR2 through the sequestration of VEGFA [116,117] and, thus, its expression may
significantly affect the efficacy of anti-angiogenic therapy. Multimerin-2 is highly expressed along
the blood vessels in the normal gastric and colonic mucosa whereas in many GI tumor-associated
vessels the expression of the molecule is significantly altered [118,119]. The loss of multimerin-2 is
partly due to the action of matrix metalloproteinase (MMP)-9 and MMP-2, the main MMPs activated
during angiogenesis [120]. MMP-9-driven degradation of multimerin-2 occurred in CRC-associated
vessels [118]. However, the loss of multimerin-2 may also be ascribed to a decreased expression of
the molecule in response to high VEGFA levels during active angiogenesis [118,121], as detected in
GC [122]. Importantly, multimerin-2 controls EC function and it is important for the maintenance of
vascular stability. In fact, the downregulation of multimerin-2 in ECs causes the dismantlement of
cell-cell junctions, leading to increased vessel permeability and leakage [123]. Thus, it is plausible
to speculate that the loss of multimerin-2 could be associated with a worse drug delivery and poor
prognosis for CRC and GC patients. The cognate protein EMILIN-2 exerts multiple functions in the
TME overall, leading to tumor-suppressive effects [124–127]. Surprisingly, the over-expression of
this matricellular protein in tumor xenografts led to the discovery of the pro-angiogenic function of
EMILIN-2 [127]. This function is unfolded though the engagement of EGFR, and the consequent
over-production of interleukin-8 (IL-8), which, in turn, stimulates EC proliferation and migration [128].
EMILIN-2 deposition nicely decorates the lamina propria of the gastric mucosa and its expression is
significantly decreased in GC [119]. The EMILIN-2 effect in GC is dual, acting directly on GC cells to
impair their proliferation and increasing the apoptotic rate and indirectly on EC and angiogenesis by
enhancing the expression of angiogenic cytokines as serine protease inhibitor 1 (SERPINE-1), VEGFA,
and IL-8 by GC cells [129]. Thus, being IL-8 at the crossroad between angiogenesis and inflammation
and a crucial cytokine in GC-associated angiogenesis [130,131], EMILIN-2 may represent a keystone in
the crosstalk between the two processes.
Like EMILIN-2, also tenascin-C (TNC) exerts multifaceted and angiomodulatory functions in the
TME [132–135]. TNC was identified as a gene associated with IBD [136], and its serum levels in these
patients correlate with the clinical and histological parameters of the disease [137]. TNC expression
increases and contributes to the modulation of inflammation in DSS-induced acute colitis and in a
mouse model of spontaneous Crohn’s disease [138], suggesting also for TNC a possible co-modulation
of both angiogenesis and inflammation. TNC expression correlates with CRC malignancy [139] and may
be considered a putative biomarker for metastasis [135,140]. Kawamura and colleagues demonstrated
that TNC promotes colitis-associated cancer development through αvβ3-mediated angiogenesis and
the disruption of this interaction is suggestive of promising therapeutic applications [141].
Another ECM molecule that modulates angiogenesis in the context of GI tumors is secreted
protein acidic and rich in cysteine (SPARC)-like protein 1 (SPARCL1), a member of the SPARC
family [142]. SPARCL1 is downregulated in various GI malignancies, such as CRC [143]. Its importance
in angiogenesis is testified by the fact that it was firstly isolated from a human high endothelial
venule (HEV) copy Deoxyribonucleic acid (cDNA) library [144] and it inhibited EC adhesion
and spreading [145], resembling the anti-angiogenic activity exerted by its closest family member,
SPARC/osteonectin [146]. Naschberger and colleagues, analyzing the transcriptome of tumor-associated
EC, demonstrated that SPARCL1 expression is progressively lost in EC derived from CRC tumors,
characterized by worse clinical prognosis [147]. This study demonstrated that SPARCL-1 regulates EC
quiescence and vessels’ homeostasis by inhibiting proliferation, migration, and angiogenic sprouting,
thus contributing to favorable prognosis.
Finally, also the role of netrins, laminin-like secreted proteins, should be mentioned, given their
established role in angiogenesis and blood vessel network formation [148]. Netrins were originally
identified as axonal guidance molecules and, in analogy with the nervous system, they act as bifunctional
modulators in angiogenesis exerting both pro- and anti-angiogenic activities [149–151]. The majority
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of CRCs harbor defects in netrin-1 receptors, highlighting the importance of this regulatory pathway in
the GI context. Netrin-1 induces angiogenic responses increasing nitric oxide production in ECs [152]
and affects EC function and filipodia formation [150,153]. Netrin-4 was shown to promote angiogenesis
in a model of post-ischemia revascularization [151] and may represent a potential alternative target
to anti-VEGFA treatments [154]. In contrast with these findings, the over-expression of netrin-4
decreased angiogenesis and CRC growth [155], as well as lymph node and lung metastasis [156],
further highlighting the bifunctional and context-dependent activity of these molecules.
Taken together, these studies highlight the prominent role of the ECM in GI tumor-associated
angiogenesis and disclose the possibility to develop less toxic anti-angiogenic therapeutic approaches
and/or predictive markers of therapy efficacy.
3. Impact of ECM on Endothelial Cells—Mechanisms of Action
The complexity of ECM is at the basis of the many different mechanisms through which it
influences ECs’ biology. Here, we gathered the different mechanisms into three main groups: (1) Direct
interaction of the ECM with EC surface receptors, (2) indirect effects due to the modulation of soluble
growth factors, and (3) mechanisms activated by mechanical forces. A schematic representation of the
main mechanisms by which the ECM affects EC function is reported in Figure 2.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 34 
 
represent a potential alternative target to anti-VEGFA treatments [154]. In contrast with these 
findings, the over-expression of netrin-4 decreased angiogenesis and CRC growth [155], as well as 
lymph node and lung metastasis [156], further highlighting the bifunctional and context-dependent 
activity of these molecules. 
Tak n together, these studies highlight the prominent role of th  ECM i  GI tumor-associated 
angiogen sis and disclose the possibility to develop less toxic anti-angiogenic therapeutic 
approaches a d/or predictive markers of therapy efficacy. 
3. Impact of ECM on Endothelial Cells—Mechanisms of Action 
The complexity f CM is t the basis of the many different mechanisms through which it 
influences ECs’ biology. Here, we gathered the different mechanisms into three main groups: (1) 
Direct interaction of the ECM with EC surface receptors, (2) indirect effects due to the modulation of 
soluble growth factors, and (3) m chanisms activated by mechanical forces. A schematic 
representation of the main mechani ms by which the ECM aff cts EC function is r ported in Figure 
2. 
 
Figure 2. Schematic representation of the major mechanisms by which ECM affects endothelial cell 
function. The ECM impacts on EC function via these major mechanisms: (1) Acting as a modulator of 
growth factors’ maturation, (2) displaying multiple binding sites for different growth factors within 
the same molecule, thus contributing to receptor clustering and signaling network, (3) affecting EC 
viability and proliferation, engaging cell surface receptors, (4) acting as stumbling block for the 
ligand/receptor interaction, (5) regulating the spatio-temporal growth factors’ availability, (6) serving 
as mechanotransducers, and (7) simultaneous binding of different receptors and modulating of their 
trafficking. 
3.1. Direct ECM-EC Interactions 
ECs are highly dependent on the ECM-derived biochemical cues, which are mainly disclosed 
through the direct engagement of cell-surface receptors such as several integrins, VEGFR2, cluster of 
differentiation (CD)36, CD44, CD93, Hyaluronan-mediated motility receptor (RHAMM), and exert 
multiple and sometimes contrasting biological effects: EC proliferation and survival, adhesion, 
migration, chemotaxis, expression of hypoxia-inducible factor 1-α (HIF-1α) and/or VEGFA, and 
apoptosis. 
Integrins, the main cell adhesion receptors, are crucial in mediating interactions between ECM 
components and EC, and a deep understanding of how these interactions affect angiogenesis may 
unveil the possibility to develop new therapeutic targets [157,158]. The major EC integrins engaging 
ECM ligands are α1β1, α2β1, αvβ3 and αvβ5, and their role was mostly investigated in the context of 
Figure 2. Schematic representation of the major mechanisms by which ECM affects endothelial cell
function. The ECM impacts on EC function via these major mechanisms: (1) Acting as a modulator of
growth factors’ maturation, (2) displaying multiple binding sites for different growth factors within
the same molecule, thus contributing to receptor clustering and signaling network, (3) affecting EC
viability and proliferation, engaging cell surface receptors, (4) acting as stumbling block for the
ligand/rece t r interaction, (5) regulating the spatio-tem oral growth factors’ availability, (6) serving
as mechanotransducers, and (7) simultan ous binding of different receptors nd modulating of
their trafficking.
3.1. Direct ECM-EC Interactions
ECs are highly dependent on the ECM-derived biochemical cues, which are mainly disclosed
through the direct engagement of cell-surface receptors such as several integrins, VEGFR2,
cluster of differentiation (CD)36, CD44, CD93, Hyaluronan-mediated motility receptor (RHAMM),
and ex rt multiple and sometimes contrasting biological effects: EC proliferation and survival,
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adhesion, migration, chemotaxis, expression of hypoxia-inducible factor 1-α (HIF-1α) and/or VEGFA,
and apoptosis.
Integrins, the main cell adhesion receptors, are crucial in mediating interactions between ECM
components and EC, and a deep understanding of how these interactions affect angiogenesis may
unveil the possibility to develop new therapeutic targets [157,158]. The major EC integrins engaging
ECM ligands are α1β1, α2β1, αvβ3 and αvβ5, and their role was mostly investigated in the context
of cancer [159]. The binding of collagen type I to the above mentioned integrins induces the
activation of p44/p42 (Erk1/Erk2) mitogen-activated protein kinase (MAPK) pathway, resulting in EC
proliferation and survival, and, thus, supporting tumor growth [160,161], whereas, collagen type IV
promotes EC migration through integrins α1β1 and αvβ3 and activation of the focal adhesion kinase
(FAK)-signaling cascade [162,163]. In contrast, its fragments, arresten, canstatin, and tumstatin, inhibit
crucial pathways that lead to angiogenesis. Arresten prevents the binding of collagen type IV to the
α1β1 integrin, resulting in MAP kinase pathway inhibition. In addition, it was also shown to inhibit
FAK phosphorylation and HIF-1α and VEGFA expression [164,165]. Integrin engagement by canstatin
leads to procaspase-9 activation through the inhibition of the FAK/PI3K (phosphoinositide 3-kinase)
pathway [166]. On the other hand, tumstatin mediates the antiangiogenic activity via the interaction
with integrin α3β1, leading to the inhibition of the hypoxia-induced cyclo-oxygenase 2 (COX-2) via the
FAK/Akt (alpha serine/threonine-protein kinase)/NF-κB pathway [167–169].
Endorepellin [77] acts through the dual engagement of α2β1 and VEGFR2, causing rapid
internalization and downregulation of both receptors, a mechanism referred to as dual receptor
antagonism [170,171], ultimately leading to transcriptional repression of HIF-1α and VEGFA, and
anti-tumor effects [172–174].
Also TSPs directly engage different integrins [175]. Binding of TSP-1 to α3β1 and α6β1 mediates
adhesion and chemotaxis, whereas α4β1 ligation stimulates cell survival and proliferation [176].
However, the effects of TSP-1 on EC behavior have been shown to occur mainly through non-integrin
receptors. In fact, both TSP-1 and TSP-2 contain thrombospondin type 1 repeat (TSR), which mediates
the interaction with CD36 [177], resulting in the phosphorylation of cellular jun (c-jun) N-terminal
kinases (JNK) and caspases and, therefore, EC apoptosis [178,179]. Increased caspases-3 activation and
EC apoptosis is also induced by TNC, despite that the mechanism has not been elucidated [180,181],
whereas netrin-1 halts EC apoptosis through the engagement of unc-5 netrin recptor B (UNC5B) and the
blockage of the death-signaling effector death-associated protein (DAP) kinase [182,183]. Furthermore,
through the engagement of CD47, but also CD36, TSP-1 inhibits the nitric oxide (NO)/cGMP (cyclic
guanosine monophosphate)-signaling pathway [184,185]. The angiogenic role of HA and, in particular,
the low molecular weight (LMW-HA) bioactive fragment, is exerted through a direct binding to CD44
and receptor for HA-mediated motility (RHAMM) [186], hence leading to mitogen-activated protein
(MAP) kinase (ERK-1/2) activation and, consequently, EC proliferation [187].
Very recent investigations identified members of the C-type lectin domain-containing group
14 family as unique receptors for multimerin-2 [188,189]. In particular, CD93 is one of the most
studied receptors of this family and plays an important role in the regulation of EC function [190].
The formation of the multimerin-2/CD93 complex is a prerequisite for the activation of integrin α5β1
and the consequent activation of the FAK cascade in ECs [191].
3.2. Indirect Mechanisms
Another important mechanism by which ECM proteins affect EC function is the interaction with
growth factors and the consequent regulation of their distribution, availability, and presentation to the
cognate receptors on the EC surface [192,193]. These multiple interactions are followed by a variety of
responses (see Figure 2).
Among the growth factors that are secreted as precursors and need to be activated in the
extracellular space, transforming growth factorβ1 (TGF-β1) plays a key role in GI cancers [194]. TGF-β1
modulates EC proliferation, tube formation, and migration in a highly context-dependent manner [195],
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and is regulated at multiple levels, including secretion and interaction with ECM components [196].
Upon secretion as a homodimer, together with its latency-associated pro-peptide (LAP), it binds to
the ECM and this interaction is further supported by covalent transglutaminase-induced crosslinks.
The localization of latent TGF-β1 to the ECM is required for effective TGF-β1 activation. Even if TSP-1
is considered one of the major endogenous modulators of TGF-β1 activation [197], recently also TSP-4
has emerged as a key element in TGFβ1-evoked angiogenesis. Notably, TSP-4, whose expression
is frequently increased in GC [198], exerts a pro-angiogenic function and associates with enhanced
vascularization [199].
Once bound to the ECM, angiogenic cytokines are released depending on their binding affinity
and the action of specific proteases [200]. Thus, the ECM releases signaling molecules at different
kinetics and from different locations, allowing an extremely tight spatio-temporal regulation of cell
fate within the TME [201]. The establishment of stable gradients through the binding with ECM
molecules impacts on the activity of the key angiogenic factor VEGFA, which, depending on its
concentration, can regulate various aspects of tumor angiogenesis [202,203]. VEGFA is upregulated
in GI cancer and represents a useful prognostic and predictive biomarker [204–206]. In the TME,
the majority of VEGFA is bound to ECM molecules as TSP-1 and -2 [175], perlecan [207], and
multimerin-2 [116,117]. The degradation of these ECM proteins is necessary to allow the engagement
of VEGFR2 and the cosequent autophosphorylation of the receptor leading to ERKs, p38 MAPK, and
p125FAK activation [208]. This VEGFA-induced signaling produces several cellular responses in ECs
including strong mitogenic and survival signals [209–211].
FGF-2 is cytokine that is tightly regulated through the binding with ECM and is altered in GI
cancers [212,213]. The binding of FGF-2 to different ECM molecules results in peculiar biological
effects: While the interaction of FGF-2 with fibronectin favors the engagement of its cognate receptors
and the activation of the downstream pathway, [214], the binding to TSP-1 and -2 sequesters the
cytokine, preventing its pro-angiogenic activity [215,216]. The absence of FGF-2 signaling results in the
decoupling of vascular endothelial (VE-cadherin and p120-catenin, leading to the loss of adherens and
tight junctions in ECs and increased vascular leakiness [217]. Once FGF-2 is released from ECM, it binds
to fibroblast growth factor receptor (FGFR) on ECs and triggers the PI3K/Akt/mTOR (mammalian
target of rapamycin) pathway, contributing to the maintenance of EC homeostasis [215].
The coexistence in the same ECM proteins of binding sites for many different growth factors
concentrates such soluble mediators close to their own cell-surface receptors favoring receptor clustering
and crosstalk. Due to its complex structure, the ECM molecule that mostly represents this function
is perlecan, which can interact with many cytokines through its protein core or the heparan sulfate
chains [207,218]. Beyond the already mentioned binding with VEGFA, perlecan interacts and modulates
the activity of several growth factors including many of the FGF family (FGF-1, FGF-2, FGF-7, FGF-9,
and FGF-18), FGF-binding protein, platelet-derived growth factor (PDGF), activin A, hepatocyte growth
factor (HGF), and progranulin [219–225]. Collectively, perlecan exerts a pro-angiogenic function by
presenting VEGFA and the various FGFs to their cognate receptors [79,217,226,227]. The simultaneous
binding of perlecan to VEGFA and FGF-2 is of peculiar interest, given the crosstalk that occurs between
these two signaling pathways [228].
The binding of growth factors to ECM molecules can also act by favoring or hampering the
engagement of the specific tyrosine kinase receptor [229]. As an example, the binding of EMILIN2
with both EGFR and EGF promotes the activation of the downstream Janus kinase/signal transducer
and activator of transcription (JAK/STAT3) pathway and leads to the overexpression of IL-8, a crucial
cytokine regulating ECs’ proliferation and migration [127,128]. Also, in GC cells the activation of the
EGF/EGFR pathway increases the production of angiogenic molecules [230,231], and this mechanism
is influenced by EMILIN2 [119]. On the other end, endostatin exerts its anti-angiogenic function
by hampering the binding of VEGFA to VEGFR2, thus resulting in decreased EC proliferation [232].
Moreover, the inhibition of VEGFA/VEGFR2 interaction by endostatin blocks VEGFA-induced EC
migration by inducing endothelial nitric oxide synthase (eNOS) dephosphorylation [220].
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Thus, the ECM is capable of integrating complex, multivalent signals in ECs in a spatially
organized and regulated fashion. In this view, ECM-bound growth factors could be released locally or
presented as complexes associated with the ECM. Such complexes could enhance membrane-proximal
regulation among the receptors and influence the integration of the transduced signals.
3.3. Mechanical Cues
It is a well-established concept that the ECM is deregulated and disorganized in solid tumors and
that the enhanced ECM stiffness is caused primarily by increased collagen deposition and enhanced
crosslinking within the stroma and promotes cancer progression [233]. ECM remodeling results
in heterogeneous three-dimensional matrix features, i.e., organization, rigidity, and composition.
The changes of the ECM mechanical forces can significantly impact on EC signaling and behavior,
resulting in the promotion of angiogenic processes [234]. In this view, the morphology and the dynamics
of the sprouting vessels are controlled also by the chemo-mechanical and geometric properties at the
capillary interface [235,236]. ECs sense and respond to mechanical cues through an interconnected
system of mechanosensors that include integrins, cell-cell adhesion receptors, receptor tyrosine kinases
(RTKs), and other membrane proteins such as ion channels and G-protein-coupled receptors. In the
tumor-associated ECs, many of these molecules become deregulated, leading to altered cell functions.
ECM stiffness induces integrin clustering in the focal adhesions, and the direct interactions between
these integrins and RTKs leads to a spatial clustering of tyrosin kinase receptors [192]. This results
in an alteration of the balance between ligand concentration and receptor auto-phosphorylation,
which amplifies ligand-induced RTK signaling [237]. Additionally, the localization of RTKs within
focal adhesions promotes the signaling through FAK, stimulating EC migration. Taken together, this
suggests that extracellular cues from the surrounding ECM do not only amplify the signaling response
from these receptors but also qualitatively change the functional outcome of RTK activation by altering
the downstream transducer activation [192]. The specific mechanosensory pathways utilized by ECs
to respond to aberrant mechanical cues are not yet well characterized, and much work still remains to
fully understand the molecular mechanisms involved. Identifying these pathways will allow a better
understanding of the mechanical regulation in tumor angiogenesis and provide new tools to govern
the physical forces in tumors.
4. Function of ECM Remodeling in GI Tumor-Associated Angiogenesis
In the complex and dynamic process of angiogenesis, the breakdown and changes of the ECM are
crucial events that reflect/impact on tumor cells but also on microenvironmental components such
as ECs, impinging on their proliferation, migration, and differentiation and, consequently/ultimately,
on the tumor vascularization. The major regulators of matrix turnover are secreted proteases, which
consist of very large families of molecules. Their mechanism of action has been well studied in various
type of malignancies, including CRC and, even if with a lower impact, GC.
MMPs are the most studied proteases involved in ECM degradation. By virtue of their role in
cleaving the ECM, they facilitate EC migration through the matrix. In turn, ECM remodeling leads to
the release of VEGFA or other ECM-bound angiogenic growth factors, or, conversely, the formation of
collagens-derived protein fragments displaying anti-angiogenic activity. Thus, MMPs are recognized
to play a key action in the context of angiogenesis (for a general review see [238]).
It is known that the local release of soluble VEGFA is a key event in angiogenesis. Following
secretion, the bioavailability of the ECM-bound VEGFA is regulated through proteolytic cleavage
aided by the acidic pH of the TME. In the colon microenvironment, MMP-2, MMP-7, MMP-9, and
MMP-14 play a pivotal role being over-expressed or hyperactive [239]. However, a direct contribution
to angiogenesis has been experimentally demonstrated only in few studies. Based on the observation
that the levels of VEGFA and MMP-9 (but not MMP-2) correlated and were mutually increased,
Hawinkels and colleagues suggested that MMP-9 could play a prominent response in the release and
bioavailability of VEGFA in CRC. These authors showed that the neutrophils-derived MMP-9 within
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the CRC microenvironment mediates the release of biologically active VEGFA through the cleavage
of heparan sulfate proteoglycans (HSPGs) [240]. In a cohort of 299 GC patients, the expression of
MMP-2, MMP-9, and VEGFA positively correlated with the tumor size, invasive depth, lymphatic and
venous invasion, lymph node metastasis and staging [241]. Despite that in this study there was no
direct proof that the MMPs’ activity impinges on angiogenesis in GC, it was in accordance with the
known prominent role of MMPs in the development of a vasculature permissive to tumor growth and
metastatic spread.
Acting on different substrates, the outcome of MMPs is a balance between pro-angiogenic and
anti-angiogenic effects; for instance, MMP-9 can also generate the angiogenic and tumor repressor
tumstatin, a fragment including the noncollagenous domain (NC1) of collagen alpha-3 (IV) [242,243].
Once released, tumstatin reduces EC proliferation and induces apoptosis through the engagement of
αVβ3 integrin [59]. On the other hand, CRC cells may be at least in part resistant to ECM-derived
anti-angiogenic stimuli. In fact, Namali and colleagues demonstrated that tumors developed following
the injection of colon cancer cells over-expressing tumstatin, endostatin, or TSP-1 finally escaped
angiogenesis inhibition [61]. The combination of all three angiogenesis inhibitors displayed no additive
effects compared to the over-expression of a single inhibitor, suggesting the presence of a functional
redundancy in this system. Interestingly, this study demonstrates that parallel pro-angiogenic pathways
can be engaged in CRC microenvironment, which may overcome the inhibitory pressure. This could
also explain the mechanisms by which CRC patients often acquire resistance to anti-angiogenic
therapy [244].
MMP-14 is another key molecule in the regulation of angiogenesis. Membrane type 1 (MT1)-MMP
belongs to the MT-MMPs’ family that includes transmembrane enzymes specialized in cleaving ECM
components adjacent to the cell surface, and its expression by ECs is vital during their migration to form
new vessels. However, the action of MT1-MMP is controversial since it can also exert anti-angiogenic
effects in a direct or indirect manner. MT1-MMP is highly expressed in CRC [245] and its expression,
together with that of α5β1 integrin, which plays a prominent role in angiogenesis [69], positively
correlates with CRC progression [246], suggesting a synergistic effect between integrin and this
enzyme. MT1-MMP can directly degrade ECM components, but also cleave cell surface molecules,
such as extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147, an inducer of MMP
expression), low density lipoprotein receptor-related protein (LRP), CD44, and cadherins [247–249].
In addition, MT1-MMP is the major activator of MMP-2 and MMP-13 [250] and plays a key role in
tube formation during angiogenesis [251]. The angiogenic function of MT1-MMP in the context of
the colon microenvironment is scantly documented; nevertheless, some evidence suggests that the
response of these degrading enzymes is extremely complex and exert their function not only towards
ECM components but also towards other bioactive substrates. For instance, MT1-MMP is known to
mediate endoglin shedding [252]. Endoglin plays a crucial role in angiogenesis, is highly expressed
on activated ECs, its expression is upregulated in various cancers [253], and is an early indicator
of the angiogenic switch in the premalignant lesions of the colon mucosa [254]. Endoglin was also
suggested to represent a putative prognostic factor for CRC patients, given the positive correlation with
angiolymphatic invasion and metastases to lymph nodes and liver [255]. The shedding of endoglin
by MT1-MMP may regulate the angiogenic potential of ECs in the CRC microenvironment [252].
The local upregulation of endothelial MT1-MMP expression increased shed endoglin (sEndoglin)
levels, decreased membrane-localized endoglin, and induced EC quiescence. This was in line with
the results conducted on 119 CRC patients where lower levels of circulating sEndoglin associated
with a higher angiogenic activity [252]. More recently, Lee and co-authors, using a rat colonic
cell line as a model, demonstrated that MT1-MMP was responsible for the degradation of the
proteoglycan syndecan-2 [256]. Through its N-terminal domain, syndecan-2 selectively promotes a
VEGFA-dependent neovascularization enhancing 6-O heparan sulfate chains’ sulfation [257]. Thus,
its cleavage by MT1-MMP may significantly impact on angiogenesis.
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In the context of GC, MT1-MMP represents a well-established prognostic factor [258,259] and
correlates with the invasion capabilities and the metastatic potential of GC cells. However, a direct
function of MT1-MMP in GC-associated angiogenesis is not yet conclusive.
Overall, these studies indicate that the role of MMPs in the context of the neovasculature associated
with the GI tumor microenvironment is complex and occasionally controversial, and is the result of
the balance between pro- and anti-angiogenic factors generated. Interestingly, the use of synthetic
inhibitors of proteases, through the blockage of MMPs and of angiogenesis, was proven useful in
reducing the metastasis of human colon cancer cells [260]. Besides MMPs, many other proteases
are involved in this process, such as plasmin, urokinase, heparanases, and phosphatidyl-inositol
phospholipase [261]. These proteases can cleave larger VEGFA isoforms into smaller fragments or,
alternatively, mediate VEGFA release from ECM.
Another important class of ECM-degrading enzymes is represented by the ‘a disintegrin and
metalloproteinase with thrombospondin motif’ (ADAMTS) family, which takes part in multiple
physiological and pathological processes [262]. In the last two decades, the involvement of ADAMTS’
proteins in vascular homeostasis as anti-angiogenic players has been widely documented. Vázquez and
colleagues functionally characterized ADAMTS1 and ADAMTS8, demonstrating for the first time that
these enzymes were able to specifically inhibit growth factor-mediated neovascularization [263].
ADAMTS1 directly binds to VEGFA through the carboxy-terminal region, suggesting that the
anti-angiogenetic activity of ADAMTS1 could be exerted through the modulation of VEGFA
bioavailability [264]. In a model of metastatic CRC, an interplay between EC-secreted ADAMTS1
and TSP-1 was identified; ADAMTS1 cleaved TSP-1, releasing anti-angiogenic fragments, which,
in turn, act locally to inhibit angiogenesis [265]. Processing of TSP-1 into anti-angiogenic fragments by
ADAMTS1 occurs much more efficiently in the liver than in lungs and thus the over-expression of
TSP-1 in the liver suppresses the vascularization of liver metastases [265]. The vascular suppression
very likely involves an apoptotic mechanism, prompted following the engagement of the EC receptor
CD36 by TSP-1 [178].
Overall, ADAMTS1 was reported to impair colon cancer progression and its expression associates
with the cancer cell aggressiveness [266]. Accordingly, the expression of the ADAMTS1 gene is
downregulated at any colon cancer stage [266].
The anti-tumor and anti-angiogenic effect displayed by ADAMTS1 has been described also in
the context of GC, where a negative correlation between ADAMTS1 and VEGFA mRNA and protein
expression was detected [267]. ADAMTS1 protein expression also negatively correlates with the
vascular density of primary gastric tumors. In contrast, in the normal gastric mucosa, in primary
gastric tumors, and in metastatic lymph nodes, no correlation was detected between ADAMTS1 and
TSP-1 mRNA and protein expression, suggesting that the interplay between ADAMTS1 and TSP-1
described in the context of CRC is not prominent in the gastric microenvironment. This evidence further
highlights the key role of the microenvironment in determining the different angiogenic properties in
CRC and GC, and, thus, the different response to anti-angiogenic therapies.
VEGFA bioavailability is also regulated via the thrombospondin type 1 repeat (TSR1) of ADAMTS5,
leading to impaired angiogenesis and tumorigenesis [268,269]. More recently, ADAMTS5 was proposed
as an independent prognostic factor for GC since its expression is downregulated by promoter
methylation with a consequent increase of GC cell migration and invasive properties, and patients
displaying higher ADAMTS5 levels are characterized by a better five-year overall survival rate [270].
Similar results to those observed for ADAMTS5 were reported for other members of the family,
such as ADAMTS8 and ADAMTS9. In GC, the methylation status of ADAMTS8 inversely correlates
with the protein expression and lower ADAMTS8 levels associate with a higher invasive depth and
with the presence of lymph node metastasis [271]. The promoters of ADAMTS8 and ADAMTS9 are
methylated also in CRC and this correlates with a decreased expression of these proteases [272–274].
Also, the hypermethylation of the ADAMTS12 gene in CRC associates with the downregulation of its
expression and impaired angiogenesis [275]. Thus, in GI cancers, ADAMTS proteins are generally
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downregulated both at the mRNA and protein levels by promoter methylation, and this correlates with
a worse prognosis for the patients. Despite the documented activity of these proteases in the regulation
of angiogenesis, in the context of GI tumors it is widely accepted. Only in some studies has an
inverse correlation between ADAMTS expression and tumor microvessel density or VEGFA expression
been clearly described [267,270,271]. However, the precise molecular mechanism behind the role of
ADAMTS proteins in vasculogenesis is still under investigation. It is possible that the anti-angiogenic
function of ADAMTS could principally rely on the regulation of cytokines’ bioavailability rather
than on the digestive activity. For instance, ADAMTS9 neither cleaved TSP-1 nor TSP-2, nor bound
VEGFA [276]. Thus, its endogenous anti-angiogenic activity on ECs is exerted through different
molecular mechanisms than those used by the related ADAMTS1 [264,265].
Several studies show that both CRC and GC are highly infiltrated by mast cells [277–282] and
the presence of these immune cells is predictive of a worse patient outcome. Mast cells are important
regulators of the angiogenic process and may be in part responsible for the resistance to anti-angiogenic
therapy [283]. Anti-angiogenic therapy stimulates mast cells to produce granzyme b (GZMB), which
in turn mobilizes the laminin- and vitronectin-bound FGF-1 and GM-CSF overcoming the blockage
of the VEGFA/VEGFR2 signaling axis [283]. Thus, the mast cells adjacent to the vessels through the
secretion of GZMB can rapidly supply the growing vasculature with ECM-derived growth factors
distinct from the one/s being blocked by the therapy, without the need of time- and energy-consuming
protein biosynthesis. However, VEGFA itself can be freed by the ECM remodeling action of GZMB.
In fact, in a model of inflammatory disease Hendel and colleagues showed that GZMB induces the
release of VEGFA from both fibronectin and EC-derived matrix resulting in a significant increase of
vascular permeability [284]. Thus, it is likely that the association between mast cell infiltration and
angiogenesis observed in CRC and GC [277–279,281,285] could hinge on the increased secretion of
GZMB and the consequent release of pro-angiogenic factors.
A distinct mechanism, other than ECM degradation, by which ECM remodeling affects
angiogenesis is mediated by the accumulation of ECM molecules generated by the activity of tissue
transglutaminase-2 (TG2), a multifunctional enzyme that catalyzes the multimerization of proteins
by generating e(g-glutamyl)lysine isopeptide bonds [286]. The cross-linking action of TG2 is exerted
towards many ECM proteins and the activity of this enzyme in ECs is thought to be important for
the stabilization of the basement membrane [287,288]. TG2 is downregulated in ECs undergoing
capillary morphogenesis, which requires localized destabilization of the matrix [289], suggesting that
this molecule is an important regulator of ECM deposition and stabilization. Jones and colleagues
demonstrated that the injection of TG2 in colon carcinoma tumors resulted in overall delay of tumor
growth and complete regression of 20% of the tumors [290]. The decreased tumor growth associated
with impaired vascularization, due to the accumulation of ECM molecules and increased cross-linking,
compromises EC tube formation and reduces angiogenesis in a dose-dependent manner. As a result,
it alters the homeostasis of ECM turnover towards deposition rather than the initial destabilization of
the matrix, which is a prerequisite for EC proliferation and migration. The mechanisms involved in
ECM remodeling in GI tumor-associated angiogenesis are schematically represented in Figure 3.
The literature pinpoints the ECM remodeling as an important actor in the vascularization of
the GI tumor microenvironment, but an extensive analysis is still required to better understand the
mechanisms of action that may grant the possibility to develop new therapies to improve the outcome
of GI cancer patients.
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5. ECM and Growth Factors in a Tangled Crosstalk
As previously mentioned, the ECM is a key regulator of growth factor availability [291], and a
deep understanding of the crosstalk between ECM and cytokines could entail new opportunities to
anti-angiogenic therapy in GI tumors.
VEGFA is the best known pro-angiogenic factor and plays a crucial role during tumor vessels’
formation [292]. Thus, many therapeutic strategies aimed at blocking this cytokine to starve tumors have
been proposed. Metastatic CRC patients can benefit from the VEGFA humanized blocking antibody
bevacizumab [34], and, in second line, from the chimeric VEGFR1/VEGFR2-based decoy receptor
VEGFA-Trap aflibercept [293]. Furthermore, patients with advanced GI stromal tumors in second-line
therapy can take advantage of sunitinib, a VEGFR2 inhibitor [294]. More recently, the VEGFR2-blocking
antibody ramucirumab has been introduced in the treatment of metastatic CRC [295] and metastatic
GC [296]. However, many patients are refractory or insensitive to anti-angiogenic therapy [297] and a
better understanding of the TME may grant the possibility to overcome this problem. Rahbari and
colleagues demonstrated that VEGFA-targeted therapy in metastatic CRC exacerbates the hypoxic
TME, leading to hyaluronic acid and sulphated glycosaminoglycans (sGAGs) accumulation. As a
consequence, increased ECM stiffness may compromise vascular perfusion, drug delivery, and, thus,
therapy efficacy [298,299]. This elegant study highlighted the need to better understand the complex
crosstalk between VEGFA and ECM in order to improve anti-angiogenic therapy in GI tumors.
As dealt with in the dedicated sections, proteases such as MMPs and ADAMTS, but also
heparanases and plasmin, are important contributors during angiogenesis, also thanks to the mediation
of VEGFA release from the ECM and the production of active VEGFA fragments [300]. The heparan
sulphate proteoglycan perlecan sequesters VEGFA, regulating its availability along the vascular BM,
thus controlling VEGFR2 activation [79]. Consistently, perlecan expression is down-modulated in
colon cancer [301] and in GC its reduction could contribute to ECs’ resistance to anoikis during
therapy [302]. Instead, as discussed in the dedicated section, multimerin-2 sequesters VEGFA, affecting
VEGFR2 angiogenic response [116–118]. Indeed, tumor-bearing mice over-expressing multimerin-2
showed impaired vascularization and reduced tumor growth [116,117], and, on the other hand,
multimerin-2 expression was lower in tumor-associated vessels in GC patients with respect to the
normal mucosa counterpart [119]. On the contrary, other ECM components are upregulated in
TME. For instance, the increased expression of the small leucine-rich repeat proteoglycan byglican
associates with poor prognosis in GC patients. Byglican induces VEGFA expression in ECs, boosting
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angiogenesis and GC growth [303]. An indirect increase of VEGFA occurs via the recruitment of cancer
associated fibroblasts (CAFs) prompted by the upregulation of laminin α1, which can also bind the
cytokine, further enhancing the pro-angiogenic response [42]. The expression of VEGFA, as well as
FGF-2, is also triggered by the fibronectin extra-domain B, the tumor-specific isoform of fibronectin,
and was shown to increase esophageal cancer vascularization [304]. FGF-2 is a potent inducer of
angiogenesis [305,306], can be sequestered by both TSP-1 and TSP-2, and hinders the activation of its
receptor, suggesting a possible strategy to overcome resistance to anti-angiogenic therapy [307–309].
Furthermore, Fuster and colleagues demonstrated that interfering with the interaction between heparan
sulfate and VEGFA/FGF-2 may potentially represent a good strategy to target tumor-associated ECs,
at least in lung cancer model [310]. However, this approach could be applied also in GI tumors,
given that the expression of heparan sulphate proteoglycans is often altered in these tumors. Of note,
FGF-2 upregulation is considered one of the possible mechanisms of acquired resistance to canonical
anti-VEGFA therapy [311,312]. The FGF-2 levels rise with disease progression and resistance to
bevacizumab [313], suggesting that the blockage of both cytokines may be beneficial. In line with
this hypothesis, the use of regorafenib, a tyrosine kinase receptor inhibitor able to block important
angiogenic receptors, including FGFR and VEGFR2, is beneficial in the treatment of metastatic CRC
and GC [314,315].
Platelet-derived growth factor B (PDGF-B) is a prominent regulator of angiogenesis, acting
autocrinally on ECs and mediating pericytes’ recruitment [316]. PDGF-B can be retained adjacent to
the EC BM proteins, such as collagens, laminins, perlecan, and nidogen, favoring pericyte migration
and association to the vessel wall. However, despite tumors often display high PDGF levels,
cancer-associated vessels exhibit poor pericyte coverage, possibly due to the increased availability
of pro-angiogenic factors, which interfere with a proper BM deposition and, thus, PDGF localization.
In addition, cancer cells frequently express platelet-derived growth factor receptor (PDGFR), becoming
sensitive to the PDGF proliferative and migratory stimuli, and in GI cancers the upregulation of PDGF
and PDGFR associates with a poor outcome [317,318]. Hosaka and colleagues demonstrated that
increased levels of tumor cell-derived PDGF induces the internalization of PDGFR in pericytes, which
then fail to properly adhere to BM proteins [319]. In fact, a combined treatment with bevacizumab and
the RTK inhibitor, imatinib, which among other receptors blocks PDGFR, induces proper deposition of
collagen IV and vessel normalization in colon cancer [320].
Angiopoietins (ANGs) regulate EC homeostasis engaging the Tie-2 receptor, and the most studied
members, ANG-1 and ANG-2, display antagonizing effects: ANG-1 stabilizes and ANG-2 supports
vessel remodeling, permeability, and proliferation [321]. ANG-1 is mainly stored in the ECM adjacent
to the EC surface, whereas ANG-2 acts more as a soluble factor [322]. ANG-2 is frequently upregulated
in CRC and GC and associates with increased metastatic potential [323,324]. Accordingly, the blockage
of ANG-2 reduces CRC growth, likely due to vessel normalization [325], and may improve anti-VEGFA
therapy in combinatorial settings [326]. The use of vanucizumab, a bispecific antibody able to block
both VEGFA and ANG-2, has been tested in a phase I clinical trial in a cohort of advanced CRC patients
with encouraging results [327]. The main therapies targeting angiogenic growth factors are reported
in Table 1.
Table 1. Summary of the major drugs targeting ECs, currently used for the treatment of GI tumors.
Antiangiogenic Drug Target Type of Molecule Cancer Type Clinical Use Ref
Bevacizumab VEGFA Blocking humanized mAb mCRC








mCRC 2nd line [293]
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Table 1. Cont.
Antiangiogenic Drug Target Type of Molecule Cancer Type Clinical Use Ref
Sunitinib VEGFR2 Small RTK inhibitor GC 2nd line [294]
Ramucirumb VEGFR2 Blocking humanized mAb mCRC/advancedGC




Regorafenib FGFR2/VEGFR2 Small RTK inhibitor mCRC/GC After the failure of otherlines of therapies [314,315]
Imatinib PDGFR Small RTK inhibitor mCRC/advancedGC
Adjuvant chemotherapy in
patients with wt PDGFR [320]
Vanucizumab ANG2/VEGFA Bi-specific mAb CRC Not approved [327]
Overall, these studies demonstrate that a better understanding of the crosstalk between the ECM
and angiogenic active growth factors may guide the development of new, promising, therapeutic
approaches for GI and other cancers.
6. Conclusions
It is widely accepted that the growth and progression of tumors does not depend only on the
nature and mutation status of tumor cells. These cells are part of a complex microenvironmental niche,
which does not represent a mere bystander during tumor development. Instead, it can profoundly
affect progression and metastatic spread, as well as therapy efficacy. In particular, the vascularization
of the tumors and the efficiency and quality of intratumoral vessels play a key role, not only in affecting
tumor growth but also in influencing hematogenous metastatic spread and drug delivery/efficacy.
As summarized here, the ECM is a master regulator of angiogenesis and vascular stability, and its
key role has also been highlighted in the context of GI cancers. Many are the molecules involved in
these phenomena, and a further layer of complexity is due to the fact that the ECM is not a stable
component; on the contrary, it is continuously rearranged, which leads to the formation of protein
fragments/peptides that may entail angiogenic properties often antagonizing those of the molecule
of origin. The balance of these components and their expression levels within the TME will finally
determine the tumor fate. Since, in GI tumors, the matrix composition changes tremendously during
development, many questions remain unanswered and intensive research will be necessary to try
develop new multi-target therapies aimed at normalizing the ECM composition to impair the metastatic
spreading and improve drug delivery and the response of GI cancer patients.
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